Literature DB >> 7836963

Prediction of outcome in multiple sclerosis based on multivariate models.

B Runmarker1, C Andersson, A Odén, O Andersen.   

Abstract

An incidence cohort of 308 multiple sclerosis patients was followed up repeatedly during at least 25 years of disease. In the patients with acute onset, multivariate survival analyses were performed and predictive models created. The endpoints DSS 6 and start of progressive disease were used. A number of variables were tested. The most important of these for prediction and therefore included in these models were: age at onset, sex, degree of remission after relapse, mono- or polyregional symptoms, type of affected nerve fibres, number of affected neurological systems. The relapse rate did not correlate with prognosis. In the predictive models, coefficients and risk ratios are provided that can be used for calculating the risk of progression and DSS 6 or to predict the median time for these endpoints in individual patients. It was also found that the risk of progression is not constant, but has a maximum a certain time after disease onset. For a patient with early onset, the risk is low in the beginning, but reaches a maximum level, which is several times higher, after about 15 years. The patient with a late onset has a much higher risk of endpoint immediately after onset, but reaches the maximum in a few years, and after that the risk decreases.

Entities:  

Mesh:

Year:  1994        PMID: 7836963     DOI: 10.1007/bf00920623

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden.

Authors:  A Svenningsson; B Runmarker; J Lycke; O Andersen
Journal:  Acta Neurol Scand       Date:  1990-09       Impact factor: 3.209

2.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

Authors:  B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

Review 3.  An epidemiological study of multiple sclerosis. Familial aggregation social determinants, and exogenic factors.

Authors:  N Koch-Henriksen
Journal:  Acta Neurol Scand Suppl       Date:  1989

4.  Early prognostic factors for disability in multiple sclerosis, a European multicenter study.

Authors:  T Riise; M Grønning; O Fernández; K Lauer; R Midgard; J M Minderhoud; H Nyland; G Pálffy; S Poser; J A Aarli
Journal:  Acta Neurol Scand       Date:  1992-03       Impact factor: 3.209

5.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

6.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

7.  Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg.

Authors:  T Broman; O Andersen; L Bergmann
Journal:  Acta Neurol Scand       Date:  1981-01       Impact factor: 3.209

8.  Restricted dissemination of clinically defined attacks in an MS incidence material.

Authors:  O Andersen
Journal:  Acta Neurol Scand Suppl       Date:  1980

9.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

10.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

View more
  13 in total

1.  Clinical characteristics and long term prognosis in early onset multiple sclerosis.

Authors:  Olivier Deryck; Pierre Ketelaer; Bénédicte Dubois
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 2.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Amr H Sawalha; Yuichiro Itoh
Journal:  Mult Scler       Date:  2018-01       Impact factor: 6.312

Review 4.  Sex-related factors in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Stefan M Gold
Journal:  Nat Rev Neurol       Date:  2012-03-27       Impact factor: 42.937

5.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

6.  Clinical characteristics of patients with late-onset multiple sclerosis.

Authors:  Bernhard Kis; Bastian Rumberg; Peter Berlit
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

7.  Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression.

Authors:  Micha Mandel; Susan A Gauthier; Charles R G Guttmann; Howard L Weiner; Rebecca A Betensky
Journal:  J Am Stat Assoc       Date:  2007-12       Impact factor: 5.033

Review 8.  Sex differences in autoimmune disorders of the central nervous system.

Authors:  Stefan M Gold; Anne Willing; Frank Leypoldt; Friedemann Paul; Manuel A Friese
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

9.  Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.

Authors:  Michael Gurevich; Tamir Tuller; Udi Rubinstein; Rotem Or-Bach; Anat Achiron
Journal:  BMC Med Genomics       Date:  2009-07-22       Impact factor: 3.063

10.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.